Portfolio news

We are delighted to announce that KPMG, is continuing its partnership with BaseLaunch to help support cutting-edge early-stage biotechs to achieve financing and grow their…

Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on…

We are proud to announce the recent expansion of our portfolio of companies. We welcome two newcomers - Incephalo and NextImmune - to our family.…

Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…

Overall, investment in Swiss biotech companies almost tripled on the previous year’s figure. It amounted to 3.44 billion Swiss francs. Investment in research and development…

Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…

“We are very excited to announce this partnership with Walder Wyss. They have advised several of our companies during their financing rounds and we have…